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Abstract
Background: Gene variants known to contribute to Autoimmune Addison’s disease (AAD) susceptibility include those at
the MHC, MICA, CIITA, CTLA4, PTPN22, CYP27B1, NLRP-1 and CD274 loci. The majority of the genetic component to disease
susceptibility has yet to be accounted for.
Aim: To investigate the role of 19 candidate genes in AAD susceptibility in six European case-control cohorts.
Methods: A sequential association study design was employed with genotyping using Sequenom iPlex technology. In
phase one, 85 SNPs in 19 genes were genotyped in UK and Norwegian AAD cohorts (691 AAD, 715 controls). In phase two,
21 SNPs in 11 genes were genotyped in German, Swedish, Italian and Polish cohorts (1264 AAD, 1221 controls). In phase
three, to explore association of GATA3 polymorphisms with AAD and to determine if this association extended to other
autoimmune conditions, 15 SNPs in GATA3 were studied in UK and Norwegian AAD cohorts, 1195 type 1 diabetes patients
from Norway, 650 rheumatoid arthritis patients from New Zealand and in 283 UK Graves’ disease patients. Meta-analysis was
used to compare genotype frequencies between the participating centres, allowing for heterogeneity.
Results: We report significant association with alleles of two STAT4 markers in AAD cohorts (rs4274624: P = 0.00016;
rs10931481: P = 0.0007). In addition, nominal association of AAD with alleles at GATA3 was found in 3 patient cohorts and
supported by meta-analysis. Association of AAD with CYP27B1 alleles was also confirmed, which replicates previous
published data. Finally, nominal association was found at SNPs in both the NF-kB1 and IL23A genes in the UK and Italian
cohorts respectively.
Conclusions: Variants in the STAT4 gene, previously associated with other autoimmune conditions, confer susceptibility to
AAD. Additionally, we report association of GATA3 variants with AAD: this adds to the recent report of association of GATA3
variants with rheumatoid arthritis.
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Introduction
Autoimmune Addison’s disease (AAD) is a rare autoimmune
endocrinopathy with a prevalence of 110–140 cases per million in
Caucasian European populations [1,2]. Like many autoimmune
endocrine conditions, AAD has a strong and oligo-genetic basis.
The first case report of monozygotic twins concordant for AAD,
suggesting a genetic aetiology, was published more than 40 years
ago [3] and a number of similar cases have since been reported [4–
6]. The observation that AAD, in common with many other
autoimmune conditions, sometimes clusters within families also
supports a genetic basis for the condition [7,8]. Furthermore,
individuals with AAD are predisposed to develop other organ-
specific autoimmune diseases which suggests shared susceptibility
loci for these conditions. Most cases of AAD are not attributable to
Mendelian abnormalities, but are a complex genetic trait, whereby
currently unknown environmental factors interact with a number
of genetic variants to cause disease.
The hypothesis-driven candidate gene approach has been used
to investigate numerous complex diseases to date. In this method,
plausible candidates are selected for investigation based on what is
known of the biology and pathophysiology of a disease, on known
allelic associations with mechanistically-related diseases and from
information gained from the investigation of monogenic forms of a
condition. In AAD such a monogenic form exists, as the
autoimmune polyendocrinopathy syndrome type 1 (APS1), caused
by loss of function mutations to both alleles of the AIRE gene [9].
In the investigation of complex AAD, the candidate gene
approach has seen a number of successes, most notably the
finding, and replication, of association of MHC alleles [10–13] and
polymorphisms in PTPN22 [14,15] and CTLA4 [16,17] with AAD,
all of which were investigated after having been associated with
related autoimmune conditions. In AAD, previous candidate gene
studies have been relatively small and some findings have proved
difficult to replicate [18,19]. Therefore, in order to attain adequate
power in candidate gene studies, large case-control cohorts are
needed. The EURADRENAL consortium has recently provided a
platform for collaboration between researchers in Europe and has,
for the first time, allowed a large number of AAD DNA samples to
be aggregated for genetic analysis.
This study aimed to investigate the role of 19 candidate genes in
the pathogenesis of AAD in six European case-control cohorts
using the Sequenom iPlex genotyping platform.
Subjects and Methods
Ethical approval for this work was obtained in each participat-
ing country as follows: Padua, Italy - Regione del Veneto Azienda
Ospedaliera di Padova (ref 1583P); Perugia, Italy - CEAS Umbria
(1247/08); Poznan, Poland - Ethics Committee at the Poznan
University of Medical Sciences (18.06.2009; decision # 540/09);
Warsaw, Poland - Ethical committee at the Center of Postgraduate
Medical Education (April 18, 2007); Sweden - Regionala
etikpro¨vningsna¨mnden i Stockholm Dnr 2008/296-31/2; Oslo,
Norway – Oslo Regional Ethics committee; Bergen, Norway -
Regional Ethics Committee West; Newcastle, UK - Leeds (East)
Research Ethics Committee, 2005 (REC reference number 05/
Q1206/144); Frankfurt, Germany - Ethical committee of the
University Hospital, Goethe-University, Frankfurt am Main
(Reference-No 49/09); New Zealand - The New Zealand Multi-
Region Ethics Committee (reference OTA/99/02/007).
Informed, written consent was sought from each study
participant at all centres with the exception of the Norwegian
controls. These samples were gathered through the national blood
donor scheme. All blood donors are informed of ongoing research
through written information and are given the opportunity to opt
out should they wish to do so. All samples collected in this way are
anonymised at source.
In each subject with AAD, the clinical diagnosis was confirmed
by either a low basal cortisol with a high ACTH level or a
subnormal response to the short synacthen test (250 mg parenteral
synthetic ACTH1–24). Patients with primary adrenal failure due to
adrenal gland infiltration or infection, with secondary adrenal
failure, or with APS1 (on the grounds of mucocutaneous
candidiasis, hypoparathyroidism, and/or ectodermal dystrophy)
were excluded. In total, DNA samples from 1,955 individuals with
AAD and 1,936 healthy controls from 6 European countries were
available for analysis. Available cohort characteristics are shown in
table 1. 21-hydroxylase (21OH) autoantibody status was not
available for all AAD cases included in this study, as it is not
routinely tested in all participating countries. In total, 1,204 cases
(61.6% of the total cohort) were known to be 21OH autoantibody
positive (21OH+): 53 from UK, 290 from Norway, 73 from
Poland, 154 from Germany, 266 from Italy and 368 from Sweden.
All control samples included were Caucasian and had no personal
or family history of autoimmune disease. Clinically silent
autoimmune disease was not excluded in these controls by
checking autoantibody levels, adrenal or thyroid function,
however 21OH positivity in controls is known to be very rare.
Members of the EURADRENAL consortium selected 19
candidate genes for investigation, based on current knowledge of
immunological pathways and the aetiology of autoimmune
conditions. These included genes influencing CD4+ lymphocyte
fate (GATA3, GATA binding protein 3; IL17A, interleukin 17A; IL17RA,
interleukin 17 receptor A; IL21, interleukin 21; IL23A, interleukin 23 alpha
subunit p19; RORA, RAR-related orphan receptor A; RORC, RAR-related
orphan receptor C; STAT2, signal transducer and activator of transcription 2;
STAT4, signal transducer and activator of transcription 4 and TBX21,
T-box 21), transcription factors which alter the immune response
(NFATC2, nuclear factor of activated T-cells, cytoplasmic, calcineurin-
dependent 2, NFKB1, nuclear factor of kappa light polypeptide gene enhancer
in B-cells 1 and REL, v-rel reticuloendotheliosis viral oncogene homolog) and
those genes important for innate immune mechanisms (CYP2R1,
vitamin D 25-hydroxylase; CYP24A1, 1,25-dihydroxyvitamin D3 24-
hydroxylase; CYP27B1, 25-hydroxyvitamin D-1 alpha hydroxylase; GC,
vitamin D binding protein; IFIH1, interferon induced with helicase C domain
1 and VDR, vitamin D receptor).
SNPs in these candidate genes were selected for genotyping
using the HapMap database tag-SNP picker (www.Hapmap.org)
[20]. SNPs were chosen with consideration of linkage disequilib-
rium (LD) patterns in CEU subjects which were studied in
Haploview [21], to ensure that the major haplotypes across each
gene were represented in the data collected, as far as possible.
Independent SNPs (those with an r2 of less than 0.4) with a minor
allele frequency (MAF) of greater than 0.1 were preferentially
selected for genotyping.
In this study, all SNP genotyping was carried out using
Sequenom MassARRAY technology (Sequenom, San Diego) at
either CIGMR, Manchester University, UK or NewGene, New-
castle University, UK. PCR reactions were set up in a 10 ml
volume and contained 30 ng of template DNA, 1.256 PCR
buffer, 1 mM MgCl2, 500 mM dNTPs and 0.5 U/reaction of Fast
Start Taq polymerase (Roche). A pool of primers (Metabion) was
made to give a final concentration of each primer of 100 nM.
Primer sequences are available from the authors on request. The
thermal cycling conditions for the reaction included an initial
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denaturation step at 94uC for 15 minutes, followed by 35 cycles of
94uC for 20 seconds, 56uC for 30 seconds and 72uC for 1 minute,
followed by a final extension step of 72uC for 3 minutes. The
iPlexTM assay was then followed according to manufacturer’s
instructions (http://www.sequenom.com).
Genotyping was undertaken in three phases, with a statistical
analysis performed after each phase. In the first phase, 85 tag
SNPs in and around the 19 chosen candidate genes were
genotyped in the UK (309 AAD, 335 controls) and Norwegian
(382 cases, 380 controls) cohorts. Genes associated with one or
both cohorts in this analysis were then selected for replication in
phase 2 of this study, where 21 SNPs in 11 genes were genotyped
in AAD case and control cohorts from Germany (341 AAD, 235
controls), Poland (275 AAD, 296 controls), Italy (280 AAD, 322
controls) and Sweden (368 AAD, 368 controls). Finally, in phase 3
of the study, 15 SNPs in the GATA3 gene were genotyped in AAD
cases and controls from the UK (335 AAD, 302 controls) and from
Norway (352 AAD, 1,353 controls). In addition, to determine
whether the association with GATA3 polymorphisms extended to
other autoimmune conditions, these SNPs were also genotyped in
a cohort of 1,195 type 1 diabetes patients and matched controls
from Norway, in 650 rheumatoid arthritis patients from New
Zealand and 452 ancestrally-matched controls and in a cohort of
283 UK Graves’ disease patients.
Data management, Quality Control and Statistical
analysis
Genotyping call rates were first calculated (AA+Aa+aa/sample
number6100) and any SNP with a call rate of less than 95% was
excluded from further analysis. Control genotype data were used
to check for Hardy-Weinberg equilibrium (HWE). SNPs out of
HWE (P,0.01) in the control population were excluded from
further analysis. The prevalence of genotypes (AA vs Aa vs aa) and
alleles (A = 2xAA+Aa, a = 2xaa+Aa) was calculated for all SNPs.
x2 testing on 262 and 362 contingency tables was used to analyse
the data for association. To account for multiple testing, a
Bonferroni correction was applied (0.05/number of independent
loci tested). Independent loci were defined as those with an r2
value, derived from Hapmap CEU data, of less than 0.4.
A meta-analysis, using the Review Manager (RevMan) Version
5.0 program (The Nordic Cochrane Centre, Copenhagen, Den-
mark [22]), was then undertaken, using a random effects model to
calculate odds ratios, confidence intervals and two-sided p-values.
The impact of heterogeneity between the cohorts was estimated
using an I2 index. Results are stated as P-values.
Results
Phase 1
Phase 1 UK cohort results. In total, alleles of 13 SNPs in 9
genes showed nominal association (P,0.05) with AAD in the UK
cohort (table 2). Maximal association was seen with the NF-kB1
gene. Six SNPs were genotyped in, and close to, this gene. Alleles
at 3 SNPs in moderate LD (r2 0.39–0.68), rs10026278, rs230532
and rs4698861, were associated with AAD in the UK cases
compared to controls. Strongest evidence for association was at
rs4698861, where the frequency of the minor (G) allele was 27.4%
in AAD cases vs 37.4% in controls [odds ratio (OR) 0.63, 95%
confidence interval (CI) 0.50–0.80; P = 0.00017)]. Haplotype
analysis in UNPHASED [23] revealed that the marker
rs4698861 accounts for all of the association with disease: if
conditioned upon, no association with other markers in close
proximity is seen. Nominal allelic association was also found at
markers in CYP24A1, CYP27B1, GATA3, IL17A, IL21, IL23A, REL
and STAT2 (table 2). Allowing for 54 independent loci tested
(P 0.05/54 =#0.00096), two of the above associations, both in
the NF-kB1 gene (rs230532 Pallele = 0.00041; rs4698861
Pallele = 0.00017) meet the threshold for significance. Full genotype
results for all cohorts can be found in File S1.
Phase 1 Norwegian cohort results. In total, 6 SNPs in 6
genes were associated with AAD in the Norwegian cohort (table 2).
Maximal association was seen at rs4274624 in the STAT4 gene. In
total, 9 SNPs were genotyped at this locus, but in this cohort, 2
were excluded (rs10931481 and rs4853543) due to low genotyping
call rates. Of the remaining 7 SNPs, only alleles at rs4274624 were
associated with AAD, with the minor (C) allele frequency being
26.9% in cases and 19.5% in controls (P = 0.00045, OR 1.52,
[95% CI 1.20–1.94]). SNPs in an additional 5 genes, IL17A,
CYP24A1, GATA3, NFKB1 and RORA showed nominal signifi-
cance. However, accounting for multiple comparisons, only
rs4274624 in STAT4 remained significantly associated
(P = 0.00045) in the Norwegian cohort.
Phase 2
Phase 2 European cohort results. Analysis of genotype
data for each of the six different European control cohorts using x2
testing indicated significant genetic heterogeneity between the
Table 1. Cohort information.
AAD cohort
Cohort size
(cases/controls)
Mean age of
onset (range) Male:Female Additional autoimmune comorbidities*
All (% of
cohort)
Autoimmune thyroid
disease (%)
Type 1 diabetes
(%)
UK 309/335 39 (10–83 years) 1:3.3 57 43 6
Norway 382/380 53 (18–95 years) 1:1.7 66 47 12
Germany 341/235 51 (22–88 years) 1:1.3 55 47 7
Italy 280/322 38 (6–84 years) 1:2.0 72 61 12
Poland 275/296 38 (9–76 years) 1:3.0 77 38 10
Sweden 368/368 34 (0–71 years) 1:1.6 62 49 11
Information for each of the six included AAD cohorts.
*Additional autoimmune comorbidities include type 1 diabetes, autoimmune thyroid disease (Graves’ and autoimmune hypothyroidism), pernicious anaemia, vitiligo,
autoimmune hepatitis, rheumatoid arthritis, SLE, Sjogren’s disease, Coeliac disease, premature ovarian failure, alopecia.
doi:10.1371/journal.pone.0088991.t001
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populations studied (table 3), with the highest levels of heteroge-
neity between control cohorts from Italy and the UK and the least
heterogeneity between the German and Swedish cohorts.
The phase 2 results for each population are summarised in
table 4. Allowing for correction in the testing of 15 independent
loci in the individual cohorts (P 0.05/15 =#0.0033), alleles at 1
marker only were significantly associated with AAD in the Italian
cohort (rs11171806 in IL23A; P = 0.0028).
Meta-analysis. Meta-analysis was performed using genotype
data from each of the 6 different patient cohorts. In total, 4 SNPs
in 3 genes remained associated with AAD. Maximal association
was seen with alleles of two SNPs in moderate LD (r2 = 0.59) in the
STAT4 gene (rs4274624 P = 0.00016; rs10931481 P = 0.0007)
(figure 1). The intronic SNP, rs4646536, in CYP27B1 was also
nominally associated in the whole cohort (P = 0.03). This marker is
in moderate LD with another genotyped SNP, rs10876993
(r2 = 0.45), however no association was seen with this SNP and
AAD (figure 1). Finally, rs3802604, an independent SNP in
GATA3, was also nominally associated with AAD (P = 0.03)
(figure 1).
When the meta-analysis was repeated including only 21OH+
AAD individuals (1,204 21OH+ compared to 1,955 individuals in
the whole AAD cohort), maximal association was again observed
at rs4274624 in STAT4 (P = 0.0003). rs3802604 in GATA3 also
remained nominally associated (P = 0.04). In addition, rs13017599
in REL was associated (P = 0.03) although the result for this SNP in
the whole AAD cohort was only marginally significant at P = 0.05.
Table 2. Associations with AAD in the UK and Norwegian cohorts in phase 1 of genotyping.
Gene
SNPs
typed
SNPs
excluded rs ID
Minor
allele
MAF cases/
controls Pgenotype/Pallele
OR
[95% CI]
LD between
associated
markers*
UK NFKB1 6 0 rs10026278 T 0.27/0.35 0.012/0.0034 0.69 [0.54–
0.88]
Moderate
rs230532 T 0.30/0.40 0.0016/0.00041 0.65 [0.52–
0.82]
rs4698861 G 0.27/0.37 0.00084/0.00017 0.63 [0.50–
0.80]
CYP27B1 3 1 rs4646536 G 0.26/0.33 0.012/0.0091 0.72 [0.56–
0.92]
Significant
rs703842 G 0.27/0.33 0.027/0.014 0.74 [0.58–
0.94]
IL23A 1 0 rs11170816 A 0.05/0.09 N/A/0.0047 0.53 [0.34–
0.84]
REL 2 1 rs13017599 A 0.41/0.33 0.0099/0.0028 1.40 [1.12–
1.76]
GATA3 4 0 rs569421 C 0.26/0.19 0.0092/0.003 1.50 [1.15–
1.96]
Low
rs444929 C 0.21/0.28 0.012/0.0053 0.69 [0.54–
0.90]
IL21 2 1 rs907715 T 0.32/0.39 0.015/0.012 0.74 [0.59–
0.93]
STAT2 2 1 rs2066808 G 0.05/0.09 0.039/0.012 0.57 [0.36–
0.90]
CYP24A1 9 3 rs4809959 G 0.48/0.53 0.012/0.046 0.80 [0.64–
0.99]
IL17A 3 0 rs16882180 T 0.32/0.38 0.13/0.043 0.79 [0.63–
1.00]
Norway STAT4 11 2 rs4274624 C 0.27/0.19 0.0013/0.00045 1.52 [1.20–
1.94]
RORA 4 1 rs1234805 T 0.37/0.30 0.0068/0.0018 1.41 [1.13–
1.75]
GATA3 4 0 rs3802604 G 0.32/0.37 0.04/0.038 0.79 [0.64–
0.98]
NFKB1 6 2 rs228611 A 0.43/0.49 0.063/0.024 0.79 [0.65–
0.97]
CYP24A1 9 1 rs2209314 C 0.25/0.25 0.031/0.91 0.99 [0.78–
1.25]
IL17A 3 1 rs4711998 A 0.22/0.27 0.060/0.039 0.77 [0.61–
0.98]
Nominally significant associations with AAD in the UK and Norwegian (italic text) cohorts in phase 1 of genotyping - no association was observed with alleles at NFATC2,
RORC, TBX21, CYP2R1, GC, IFIH1, IL17RA and VDR (data not shown). Pgenotype and Pallele denote the P values derived from 263 and 262 chi squared testing respectively.
*Low LD = r2,0.40, moderate LD = r2 0.40–0.79, significant LD = r2.0.79.
If the minor genotype was not represented in the dataset, the Pgenotype result is recorded as N/A.
doi:10.1371/journal.pone.0088991.t002
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No association was observed with rs10931481 in STAT4 (P = 0.07)
or with rs4646536 in CYP27B1 (P = 0.16).
Extension of GATA3 analysis
The nominal association of GATA3 alleles with AAD in UK,
Norwegian and Polish cohorts, that remained associated following
meta-analysis, was a novel finding (tables 2 and 4), as at the time of
this study, polymorphisms in the GATA3 gene have not previously
been associated with autoimmune conditions. This locus was
therefore selected for more detailed genotyping in the AAD
cohorts and in additional disease cohorts: 1,195 Norwegian
subjects with type 1 diabetes, 650 New Zealand subjects with
rheumatoid arthritis and 283 UK subjects with Graves’ disease.
GATA3 results
Allowing for 5 independent comparisons at the GATA3 locus
(P 0.05/5 =#0.01), 2 SNPs in the UK AAD cohort (rs569421
P = 0.0096; rs422628= P 0.01) remained significantly associated. A
further SNP in the New Zealand rheumatoid arthritis cohort
(rs3802604 P = 0.0096) would also meet the significance threshold.
rs3802604 was associated with AAD in the meta-analysis, however
in AAD the minor G allele appears to confer protection from
disease in contrast to rheumatoid arthritis, where the G allele
confers disease susceptibility.
Table 3. Genetic heterogeneity between the six different
European control cohorts.
UK Norway Germany Italy Poland Sweden
UK 16.7% 21.4% 73.3% 53.3% 46.7%
Norway 7.7% 64.3% 30.8% 14.3%
Germany 50.0% 5.3% 0.0%
Italy 60.0% 57.1%
Poland 20.0%
Sweden
Genetic heterogeneity between the six different European control cohorts.
Allele frequencies were compared between all control populations using a chi
squared test. The percentage of comparisons where a statistically significant
result was seen (P,0.05) is shown in the table. A low percentage indicates that
there were few markers at which allele frequencies differed between 2
populations of interest suggesting that there is little genetic heterogeneity
between those two populations. A high percentage indicates that allele
frequencies between two populations differed significantly at multiple markers,
suggesting significant genetic heterogeneity between those two populations.
Between the German and Swedish control cohorts, allele frequencies did not
differ significantly at a single marker, suggesting that these populations are
relatively genetically similar. By contrast, the UK and Italian control cohorts
differed significantly at 73% of markers tested, suggesting significant genetic
heterogeneity between these two cohorts.
doi:10.1371/journal.pone.0088991.t003
Table 4. Associations with AAD in the German, Swedish, Italian and Polish cohorts in phase 2 of genotyping.
Gene
SNPs
typed
SNPs
excluded rs ID
Minor
allele
MAF
cases/controls Pgenotype/Pallele
OR [95%
CI]
LD between
associated
markers*
Germany
IL21 2 0 rs907715 T 0.24/0.31 0.0078/0.018 0.73 [0.56–
0.95]
Sweden
STAT4 3 0 rs4274624 C 0.29/0.24 0.056/0.017 1.33 [1.10–
1.68]
Italy
STAT4 3 0 rs10931481 G 0.36/0.29 0.016/0.0056 1.41 [1.11–
1.80]
Moderate
rs4274624 C 0.28/0.22 0.059/0.02 1.37 [1.10–
1.78]
IL23A 1 0 rs11171806 A 0.06/0.03 0.012/0.0028 2.37 [1.32–
4.23]
NFKB1 3 0 rs10026278 T 0.27/0.23 0.049/0.078 1.27 [0.97–
1.65]
STAT2 2 0 rs2066808 G 0.07/0.04 0.037/0.014 1.93 [1.13–
3.28]
Significant
rs2066807 G 0.06/0.03 0.023/0.0063 2.18 [1.23–
3.85]
Poland
IL21 2 0 rs2221903 C 0.31/0.38 0.04/0.02 0.75 [0.58–
0.96]
CYP24A1 1 0 rs4809959 G 0.56/0.49 0.11/0.03 1.29 [1.02–
1.64]
GATA3 3 0 rs444929 C 0.18/0.21 0.03/0.12 0.79 [0.59–
1.06]
Nominally significant associations with AAD in the German, Swedish, Italian and Polish cohorts in phase 2 of genotyping. No association was observed with alleles at
RORA, IL17A, CYP27B1 and REL (data not shown).
*Low LD = r2,0.40, moderate LD = r2 0.40–0.79, significant LD = r2.0.7.
doi:10.1371/journal.pone.0088991.t004
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Figure 1. Forest plots of significant meta-analysis results in AAD. Meta-analysis of rs4274624 and rs10931481 in the STAT4 gene (panel A, B),
rs4646536 SNP in the CYP27B1 gene (panel C) and rs3802604 SNP in the GATA3 gene (panel D) in 6 European AAD cohorts. To be included in the
analysis, the genotyping call rate per SNP had to be 95% or more for each cohort, in both cases and controls, and the control data set had to not
deviate significantly from Hardy Weinberg Equilibrium (P.0.01). Pooled analysis showed little heterogeneity amongst the cohorts (I2#20%). Using a
random effects model, the meta-analysis confirms association between alleles at these four SNPs and AAD. Maximum association was noted at
rs4274624 (panel A), with an odds ratio (OR) of 1.27 [95% CI 1.12–1.42), P,0.0001. (*P value = 0.00016 when data analysed under a random effects
model in Stata). In panel B, data for the UK and Norwegian cohorts is not presented as the quality control inclusion criteria were not met in these
cohorts.
doi:10.1371/journal.pone.0088991.g001
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Discussion
This is the largest study of AAD genetics to date, including
almost 2,000 AAD subjects from six European countries. It
implicates a number of biomolecular pathways in the pathogenesis
of this rare autoimmune condition.
The most robust finding of this study is association of AAD with
alleles at two STAT4 markers. The STAT4 transcription factor is
known to have a role in CD4+ cell fate, being necessary for
generation of TH1 responses, and also plays a role in TH17 cell
differentiation. Variation at the STAT4 locus is well established as
having a role in several different autoimmune conditions including
rheumatoid arthritis [24,25], SLE [23] and primary Sjo¨gren’s
disease [26]. In the study by Remmers et al. [24] the minor allele at
STAT4 marker rs7574865 was significantly associated with both
rheumatoid arthritis (P = 4.6461028, OR 1.27 [95% CI 1.16–
1.36]) and SLE (P = 1.8761029, OR 1.55 [95% CI 1.34–1.79] in
a meta-analysis. The minor allele of this SNP, in addition to three
others in intron 3 of STAT4, was also associated with rheumatoid
arthritis in the Korean population (P = 0.0065, OR 1.27 [95% CI
1.11–1.45]) [25] and with primary Sjo¨gren’s syndrome in a small
study (P = 0.01, OR 1.47 [95% CI 1.09–1.97]) [26]. The marker
most associated with AAD in the meta-analysis performed in this
study, rs4274624, is in significant LD (r2 = 0.90) with SNP
rs7574865. The other associated marker, rs10931481, in the
meta-analysis, is in moderate LD with both rs4274624 (r2 = 0.59)
and rs7574865 (r2 = 0.53) and was further associated with
rheumatoid arthritis and SLE directly in the study by Remmers
(P = 0.005, 0.025 respectively) [24], but to a lesser degree than
rs7574865. These SNPs are all within a large intron in the STAT4
gene which raises the possibility that they are tagging a variant
which, rather than disrupting protein structure and/or function
directly as deleterious mutations in the coding regions might, may
result in splice variation or disrupt non-coding regulatory
components to result in disease susceptibility.
Furthermore, we demonstrated nominally significant association
of GATA3 polymorphisms in UK, Norwegian and Polish AAD
populations, and meta-analysis of the whole European AAD
cohort further supported this association. GATA3 has been
implicated in the homeostasis and regulation of CD8+ T-
lymphocytes [27] and could therefore contribute to primary
T-lymphocyte dysregulation in autoimmune Addison’s disease.
Extension of GATA3 analysis to other autoimmune disease cohorts
showed only association with alleles at a single SNP, rs3802604, in
the New Zealand rheumatoid arthritis population, replicating a
recent finding in a large multinational RA patient cohort [28].
This is the SNP that was associated in the AAD cohort meta-
analysis, however for AAD, the minor G allele is protective (OR
0.90), whereas in rheumatoid arthritis, the minor G allele confers
susceptibility (OR 1.27). Although this may represent a novel but
different association in rheumatoid arthritis, reflecting the different
immunopathogenesis of this disease compared to AAD, the overall
degree of association in AAD is weak and this finding needs further
replication in larger datasets.
We have also replicated the association of CYP27B1 polymor-
phisms with AAD. Association of a promoter polymorphism in this
gene with German autoimmune cohorts, including AAD,
Hashimoto’s thyroiditis, Graves’ disease and type 1 diabetes was
first reported in 2004 [29]. This finding was later replicated in
small AAD cohorts from the UK and Poland [30,31]. In this study,
we have used meta-analysis to establish an association with an
intronic variant in this gene and AAD in European cohorts. There
is strong linkage disequilibrium in this region which encompasses
the entire CYP27B1 gene and therefore these associated SNPs may
be tagging a more distant causative variant yet to be defined.
Alternatively, polymorphisms in CYP27B1, also associated with
type 1 diabetes [32] may have a role in regulating vitamin D 1-
alpha hydroxylation in a tissue-specific manner [33].
Finally, we report significant association with alleles at NF-kB1
polymorphisms and AAD in the UK cohort and between alleles of
an IL23A polymorphism and AAD in the Italian cohort. The NF-
kB pathway is a highly conserved innate immune mechanism
which allows a vigorous and rapid inflammatory response to a
myriad of potentially harmful stimuli, and IL23A has a role in
CD4+ cell fate and the TH1 response, therefore these are both
plausible candidates for AAD. However, the significance of these
isolated findings is currently unclear and these results will need to
be confirmed by replication.
We observed significant genetic heterogeneity between the 6
European control cohorts, particularly between geographically
distant countries such as the UK and Italy and this may explain
the different patterns of associations between the 6 European AAD
cohorts. Genetic heterogeneity may also be contributing to the
differences observed in the clinical characteristics of the partici-
pating European cohorts, for example the age at onset of AAD
and the proportion of each cohort with additional autoimmune
conditions. However, variation between countries in diagnostic
criteria and how these data are recorded and collected is also likely
to be a contributing factor to these observed differences. Previous
studies have also demonstrated significant genetic heterogeneity
between European countries, even when non-Caucasian individ-
uals are excluded. For example, a study by Cross et al. published in
2010 [34] compared allele frequencies of 51 SNPs in 19,027 self-
reported white Caucasians. Between individuals from Scandinavia,
the UK, Germany and Eastern Europe, minor allele frequencies
differed significantly (i.e. P,0.05) at 19 (37.3%) SNPs. The
difference was particularly marked (i.e. P,0.0001) at 5 (9.8%) of
the 51 SNPs analysed. The significant heterogeneity observed
between the 6 countries included in this study may account for the
different patterns of association in each population and clearly
highlights the importance of carefully matching cases with controls
in genetic studies.
Conclusion
This is the largest genetic study of AAD to date and includes
almost 2,000 carefully phenotyped individuals from 6 European
countries. We have demonstrated significant heterogeneity
between control cohorts of the participating European countries.
We report that variants in the STAT4 gene, previously associated
with other autoimmune conditions including rheumatoid arthritis
and SLE, appear to confer susceptibility to AAD, as demonstrated
by data derived from the Italian, Norwegian and Swedish
populations studied. We are also able to confirm a nominal
association of GATA3 variants with another autoimmune condi-
tion, namely AAD, in UK, Norwegian and Polish Europeans. On
further investigation, a single SNP was also associated with
rheumatoid arthritis in a cohort from New Zealand, however, the
findings could not be replicated in type 1 diabetes or Graves’
disease. In addition, we have replicated a previous association with
CYP27B1 polymorphisms with AAD in the UK cohort, with the
result supported by meta-analysis in the six European cohorts
together. We have found that variants in two genes, NF-kB1 and
IL23A, not previously associated with AAD, contribute to
susceptibility in the UK and Italian populations respectively,
however these findings require replication. Further research,
perhaps by genome-wide association studies in large, collabora-
tive cohorts, or whole exome/genome sequencing in selected
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individuals, is now warranted to determine the genetic factors
which make up the remaining hidden heritability of AAD.
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